Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) or certain of its officers and directors violated federal securities laws by misrepresenting or failing to timely disclose material information to investors.

What if I purchased Capricor securities?

If you purchased Capricor securities and suffered losses on your investment, you may join our investigation now: Click Here to Join the Investigation.

Or for more information, contact James Baker at jimb@johnsonfistel.com or (619) 814-4471.

There is no cost or obligation to you.

What is Johnson Fistel Investigating?

On July 27, 2026, the FDA released briefing documents raising concerns about the evidence supporting deramiocel. FDA staff questioned Capricor’s analysis of the HOPE-3 trial, stating that the conversion of results was not “scientifically justified” because it “adds complexity and reduces accuracy.” FDA staff further concluded that “the benefit-risk assessment for deramiocel appears unfavorable in the absence of evidence of effectiveness.”

On July 29, 2026, the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted 9 to 3, with no abstentions, that the available evidence did not support deramiocel’s effectiveness in treating cardiomyopathy in patients with Duchenne muscular dystrophy. The committee’s vote is nonbinding.

Following the release of the FDA briefing documents, Capricor’s stock price declined approximately 65% on July 27, 2026. The stock fell sharply again on July 30 following the committee vote, resulting in significant losses for investors.

Investors who purchased Capricor securities and suffered losses are encouraged to contact Johnson Fistel to discuss their rights and potential recovery options. There is no cost or obligation to participate.

About Johnson Fistel, PLLP

Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit www.johnsonfistel.com.

Attorney advertising.

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices.

Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260730442103/en/

Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) or certain of its officers and directors violated federal securities laws.